These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10520033)

  • 41. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Alexandrakis MG; Passam FH; Sfiridaki A; Kandidaki E; Roussou P; Kyriakou DS
    Am J Hematol; 2003 Apr; 72(4):229-33. PubMed ID: 12666132
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Importance of selected laboratory indicators in the differential diagnosis and monitoring of multiple myeloma].
    Maisnar V; Tousková M; Malý J; Krejsek J; Kmonícek M; Kopecký O
    Vnitr Lek; 2002 Apr; 48(4):290-7. PubMed ID: 12061177
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical correlates of elevated serum levels of interleukin 6 in patients with untreated Hodgkin's disease.
    Seymour JF; Talpaz M; Hagemeister FB; Cabanillas F; Kurzrock R
    Am J Med; 1997 Jan; 102(1):21-8. PubMed ID: 9209197
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum levels of soluble IL-6 receptor in multiple myeloma as indicator of disease activity.
    Papadaki H; Kyriakou D; Foudoulakis A; Markidou F; Alexandrakis M; Eliopoulos GD
    Acta Haematol; 1997; 97(4):191-5. PubMed ID: 9158660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cytokine expression in multiple myeloma and monoclonal gammopathy: analysis by reverse transcription/polymerase chain reaction and quantitative PCR.
    Soutar RL; Dillon JM; Brown D; Ralston SH
    Leuk Lymphoma; 1996 Dec; 24(1-2):111-20. PubMed ID: 9049967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Serum oncostatin M in multiple myeloma: association with prognostic factors.
    Koskela K; Pelliniemi TT; Remes K; Rajamäki A; Pulkki K
    Br J Haematol; 1997 Jan; 96(1):158-60. PubMed ID: 9012701
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control.
    Paiva B; Vídriales MB; Rosiñol L; Martínez-López J; Mateos MV; Ocio EM; Montalbán MÁ; Cordón L; Gutiérrez NC; Corchete L; Oriol A; Terol MJ; Echeveste MA; De Paz R; De Arriba F; Palomera L; de la Rubia J; Díaz-Mediavilla J; Granell M; Gorosquieta A; Alegre A; Orfao A; Lahuerta JJ; Bladé J; San Miguel JF;
    Leukemia; 2013 Oct; 27(10):2056-61. PubMed ID: 23743858
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.
    Filella X; Blade J; Guillermo AL; Molina R; Rozman C; Ballesta AM
    Cancer Detect Prev; 1996; 20(1):52-6. PubMed ID: 8907203
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Usefulness of a free light chain immunoassay in serum for the diagnosis and the follow-up of monoclonal gammopathy].
    Guenet L; Decaux O; Lechartier H; Ropert M; Grosbois B
    Rev Med Interne; 2007 Oct; 28(10):689-97. PubMed ID: 17566612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.
    Ely SA; Knowles DM
    Am J Pathol; 2002 Apr; 160(4):1293-9. PubMed ID: 11943714
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple myeloma presenting high fever and high serum levels of lactic dehydrogenase, CRP, and interleukin-6.
    Murakami H; Takada S; Hatsumi N; Yokohama A; Saitoh T; Uchiumi H; Maehara T; Matsushima T; Tsukamoto N; Morita K; Tamura J; Sawamura M; Karasawa M
    Am J Hematol; 2000 May; 64(1):76-7. PubMed ID: 10815794
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma.
    Woitge HW; Pecherstorfer M; Horn E; Keck AV; Diel IJ; Bayer P; Ludwig H; Ziegler R; Seibel MJ
    Br J Cancer; 2001 Feb; 84(3):344-51. PubMed ID: 11161399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Clinical significance of soluble interleukin-2 receptor in multiple myeloma].
    Akimoto Y; Ishiyama T; Ueno H; Hino K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1995 Nov; 36(11):1247-51. PubMed ID: 8691563
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical significance of elevated soluble interleukin-6 receptor levels in the sera of patients with plasma cell dyscrasias.
    Ohtani K; Ninomiya H; Hasegawa Y; Kobayashi T; Kojima H; Nagasawa T; Abe T
    Br J Haematol; 1995 Sep; 91(1):116-20. PubMed ID: 7577617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Prognostic value of serum IL-6 in patients with multiple myeloma].
    Xing LJ; Xu Y; An G; Deng SH; Sui WW; Li F; Zhou DH; Zhao YZ; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Dec; 21(6):1492-5. PubMed ID: 24370035
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma.
    Terpos E; de la Fuente J; Szydlo R; Hatjiharissi E; Viniou N; Meletis J; Yataganas X; Goldman JM; Rahemtulla A
    Int J Cancer; 2003 Sep; 106(3):455-7. PubMed ID: 12845688
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interleukin-6 in multiple myeloma: correlation with disease activity and Ki-67 proliferation index.
    Thaler J; Fechner F; Herold M; Huber H
    Leuk Lymphoma; 1994 Jan; 12(3-4):265-71. PubMed ID: 8167557
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cytobiological studies in multiple myeloma.
    Pileri A; Massaia M; Dianzani U; Omedè P; Boccadoro M
    Acta Haematol; 1987; 78 Suppl 1():41-2. PubMed ID: 2829488
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [IL-6, p53 and proto-oncogene c-myc play different roles as biological markers of plasma cell dyscrasias].
    Alvino S; Marcucci M; Canzoniere D; Mosiello A; Del Monte G; Venturo I; Rinaldi M; Gandolfo GM; Lopez M; Greco C
    Clin Ter; 1999; 150(3):197-202. PubMed ID: 10528431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Paraproteinaemia.
    Br Med J; 1980 Feb; 280(6210):273-4. PubMed ID: 7357337
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.